Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for.
AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene s New Cell Therapy Product finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization , today announced a new service agreement with Medigene AG . Under the agreement, AGC Biologics.
Planegg/Martinsried, October 23, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors,